The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review
出版年份 2018 全文链接
标题
The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review
作者
关键词
Nivolumab, Immune-checkpoint inhibitor, Diarrhoea, Colitis, Ulcerative colitis
出版物
BMC GASTROENTEROLOGY
Volume 18, Issue 1, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-08-31
DOI
10.1186/s12876-018-0864-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer
- (2017) Tomoyoshi Takenaka et al. INVESTIGATIONAL NEW DRUGS
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- (2016) L. Marthey et al. Journal of Crohns & Colitis
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- European consensus on the histopathology of inflammatory bowel disease
- (2013) F. Magro et al. Journal of Crohns & Colitis
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- A new paradigm in ulcerative colitis: Regulatory T cells are key factor which induces/exacerbates UC through an immune imbalance
- (2012) Hiroyuki Hanai et al. MOLECULAR IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blockade of Cytotoxic T-lymphocyte Antigen-4 by Ipilimumab is Associated with a Profound Long-Lasting Depletion of Foxp3+ Regulatory T Cells: A Mechanistic Explanation for Ipilimumab-Induced Severe Enterocolitis?
- (2011) S. Nancey et al. INFLAMMATORY BOWEL DISEASES
- Lymphocytic Colitis Secondary to Ipilimumab Treatment
- (2011) Alejandro García-Varona et al. INFLAMMATORY BOWEL DISEASES
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo
- (2009) S. Chikuma et al. JOURNAL OF IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started